Stephane Bancel - Mar 1, 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role: Chief Executive Officer, Director
Signature: /s/ Brian Sandstrom, as Attorney-in-Fact
Stock symbol: MRNA
Transactions as of: Mar 1, 2022
Transactions value $: -$1,344,960
Form type: 4
Date filed: 3/3/2022, 03:49 PM
Previous filing: Feb 25, 2022
Next filing: Mar 4, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MRNA	Common Stock	Gift		-150K	-2.64%		5.53M	Mar 2, 2022	Direct	F1
transaction	MRNA	Common Stock	Sale	-$1.34M	-9K	-0.16%	$149.44	5.53M	Mar 2, 2022	Direct	F2
transaction	MRNA	Common Stock	Gift		-4K	-0.07%		5.52M	Mar 2, 2022	Direct	F1, F3
holding	MRNA	Common Stock						9.05M	Mar 1, 2022	See Footnote	F4
holding	MRNA	Common Stock						7M	Mar 1, 2022	See Footnote	F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MRNA	Stock Option (Right to Buy)	Award	$0	+146K		$0.00	146K	Mar 1, 2022	Common Stock	146K	$149.52	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported disposition represents a bona fide charitable gift made by the reporting person.
F2	This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as amended on May 21, 2020.
F3	The reported disposition was effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2020, as amended May 13, 2021.
F4	These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F5	These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F6	25% of this option will vest and become exercisable on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.